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The critical path
The focus of the FDA’s Critical Path initiative includes: 
Assessing safety.•	
Demonstrating medical and/or public health utility. •	
Industrialization.•	
Equally important elements in delivering the product to the 
user include:
Ensuring regulatory approval.•	
Establishing licensing and distribution channels.•	
Seeding and developing markets.•	
Negotiating financing and procurement mechanisms.•	
Generating demand among potential users, providers, •	
and policymakers.
Developing service delivery guidelines and training.•	
Creating an enabling policy environment.•	
Planning for scaling up.•	
The Population Council is an international nonprofit, 
nongovernmental organization that conducts bio-
medical, social science, and public health research 
on HIV and AIDS; poverty, gender and youth; and 
reproductive health (RH). Our work cuts across disci-
plines, geographies, and the public and private sec-
tors. The Population Council develops and tests the 
effectiveness and acceptability of new and improved 
health technologies, including contraceptives and 
microbicides, which are designed to benefit women 
and men in developing countries. Our work includes 
user’s perspectives throughout the development 
and introduction process. In addition, we encourage 
licensing, registration, manufacturing, and distribution 
of contraceptive and other RH technologies devel-
oped by the Council.
Council’s work on product development
The Population Council has developed and licensed some of 
the most widely used long-acting, reversible contraceptives in 
the world. Our work includes basic research directed toward 
fundamental understanding of biology and disease processes, 
providing the foundation for product development, as well 
as translational research which employs novel techniques and 
tools in the lab, and innovative approaches in field programs to 
ensure that our scientific discoveries translate into improving 
the lives of women and men around the globe.
As a product developer we know what is required to take 
an innovation to a viable product. Product developers must 
negotiate scientific and technical dimensions along the critical 
path from innovation to commercial product. Whether work-
ing with drugs, devices, or biologics—or some combination 
thereof—our experience suggests that this pathway encompass-
es scientific, technical, programmatic and policy dimensions. 
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Scientific, technical, Programmatic, and Policy dimenSionS of a critical Path
dimension Definition  Illustrative Activities 
Assessing safety* Show that the product is 
adequately safe for each 
stage of development
Pre-clinical•	
Show that product is safe enough for human testing 
Eliminate products with safety problems  
Clinical •	
Show that product is safe enough for use in humans  
Identify potential issues with labeling 
Demonstrating  
medical and/or  
public health utility*
Show that the product 
benefits	people	who	will	
eventually use it
Pre-clinical: Select appropriate design (devices) or •	
candidate (drugs) with high probability of effectiveness 
Clinical•	
Show effectiveness in people 
Evaluate acceptability among users 
Industrialization/
manufacturing*
From lab concept or 
prototype to a reliably 
manufactured product
Design a high-quality product: physical design, •	
characterization,	specifications
Develop production capacity for:•	
Manufacturing scale-up 
Quality control 
Transfer of technology 
Ensuring regulatory 
approval 
Approval of product by 
regulatory authorities 
(e.g., FDA, EMA, SRAs)
Determine regulatory pathway; engage regulatory bodies •	





Identify suitable licensing and distribution entities •	




Mechanism for bulk  
purchasing	and	financing	
Establish	public	sector	pricing	and	financing	arrangements•	
Engage donors around procurement•	
Conduct strategic demand forecasting•	
Demand generation Transform unmet need 
into user demand
Create awareness among users, providers, and •	
policymakers
Engage advocacy, civil society, and women’s groups•	
Identify market segments, advertising and pricing strategies•	
Document user perspective•	
Fostering an enabling 
policy environment
Incorporate into  
international guidelines 
and national norms 
Issue WHO guidelines•	
Develop country service delivery protocols •	
Identify and train providers and key opinion leaders•	
Conduct implementation research to identify best ways to •	
expand access and improve quality
Scaling up Take product to 
mainstream
Prepare introduction strategy with local stakeholders•	
Assess acceptability under routine service conditions•	
Conduct implementation research and measure and •	
evaluation 
  
